Susceptibility Profiles of<i>Mycobacterium ulcerans</i>Isolates to Streptomycin and Rifampicin in Two Districts of the Eastern Region of Ghana

Owusu, Enid; Newman, Mercy J.; Kotey, Nana Konama; Akumwena, Amos; Bannerman, Elizabeth

doi:10.1155/2016/8304524

Cited by 13 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…tuberculosis . Current methodologies to perform susceptibility testing against clinical isolates are often time consuming and cumbersome (use of agar proportion methods), thus, requiring several months to generate results [6, 8, 26]. Improvements have been introduced using luminescent reporter strains [45]; however, this technology is limited to specific engineered strains and cannot be widespread applied to clinical isolates.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, an alternative drug regimen would be required to treat resistant M . ulcerans strains [26], even though the emergence of resistance in M . ulcerans might follow different dynamics compared to M .…”

Section: Discussionmentioning

confidence: 99%

“…ulcerans strains resistant to rifampicin have been isolated after experimental chemotherapy in mice [25] and a recent report described the emergence of M . ulcerans strains resistant to rifampicin and streptomycin in the clinic [26]; further experiments would be, however, needed to identify the genetic basis of such resistance patterns and confirm the emergence of resistance in M . ulcerans clinical isolates.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening

et al. 2019

View full text Add to dashboard Cite

The potential use of clinically approved beta-lactams for Buruli ulcer (BU) treatment was investigated with representative classes analyzed in vitro for activity against Mycobacterium ulcerans. Beta-lactams tested were effective alone and displayed a strong synergistic profile in combination with antibiotics currently used to treat BU, i.e. rifampicin and clarithromycin; this activity was further potentiated in the presence of the beta-lactamase inhibitor clavulanate. In addition, quadruple combinations of rifampicin, clarithromycin, clavulanate and beta-lactams resulted in multiplicative reductions in their minimal inhibitory concentration (MIC) values. The MIC of amoxicillin against a panel of clinical isolates decreased more than 200-fold within this quadruple combination. Amoxicillin/clavulanate formulations are readily available with clinical pedigree, low toxicity, and orally and pediatric available; thus, supporting its potential inclusion as a new anti-BU drug in current combination therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening

et al. 2019

View full text Add to dashboard Cite

show abstract

“…investigated the susceptibility profiles of 70 MU isolates from 2 BU endemic areas in Ghana to SR at critical concentrations of 40 μg/mL and 4 μg/mL, by the Canetti proportion method. The authors reported 17.1% resistance to rifampicin and 2.9% to streptomycin . The outcome although does not reflect all BU endemic areas, still it is essential for antibiotic stewardship in terms of disease surveillance and control.…”

Section: Prolong Viability Of Mu In Bu Lesionsmentioning

confidence: 90%

Challenges associated with the treatment of Buruli ulcer

Aboagye

Kpeli

Tuffour³

et al. 2018

Journal of Leukocyte Biology

View full text Add to dashboard Cite

Buruli ulcer (BU), caused by Mycobacterium ulcerans (MU), is the third most important mycobacterial diseases after tuberculosis and leprosy in immunocompetent individuals. Although the mode of transmission remains an enigma, disease incidence has been strongly linked to disturbed environment and wetlands. The blunt of the diseases is recorded in West African countries along the Gulf of Guinea, and children 15 years and below account for about 48% of all cases globally. Prior to 2004, wide surgical excisions and debridement of infected necrotic tissues followed by skin grafting was the accepted definitive treatment of BU. However, introduction of antibiotic therapy, daily oral rifampicin (10 mg/kg) plus intramuscular injection of streptomycin (15 mg/kg), for 8 weeks by the WHO in 2004 has reduced surgery as an adjunct for correction of deformities and improved wound healing. An all-oral regimen is currently on clinical trial to replace the injectable. It is thought that a protective cloud of the cytotoxic toxin mycolactone kills infiltrating leucocytes leading to local immunosuppression and down-regulation of the systemic immune system. Our studies of lesions from BU patients treated with SR have demonstrated treatment-associated initiation of vigorous immune responses and the development of ectopic lymphoid tissue in the BU lesions. Despite these interventions, there are still challenges that bedevil the management of BU including paradoxical reactions, evolution of lesions after therapy, prolong viability of MU in BU lesions, and development of secondary bacterial infection. In this paper, we will mainly focus on the critical and pertinent challenges that undermine BU treatment toward effective control of BU.

show abstract

“…These diseases continue to be major global health concerns, due to a marked increase in the number of susceptible individuals (Bruchfeld et al, 2015;Chao et al, 2020;Amoako et al, 2021) and associated prejudicial direct and secondary effects on global health and economy (Saraya et al, 2012). Moreover, the increasing antimicrobial resistance limits the efficacy of the reduced number of compounds available for treatment, stressing the need for expansion of surveillance and development of novel therapeutic and disease control strategies (Owusu et al, 2016;Gygli et al, 2017;Cambau et al, 2018).…”

Section: The Burden Of Mycobacterial Diseasesmentioning

confidence: 99%

The impact of single-cell genomics on the field of mycobacterial infection

Geraldes

Fernandes²,

Fraga³

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

Genome sequencing projects of humans and other organisms reinforced that the complexity of biological systems is largely attributed to the tight regulation of gene expression at the epigenome and RNA levels. As a consequence, plenty of technological developments arose to increase the sequencing resolution to the cell dimension creating the single-cell genomics research field. Single-cell RNA sequencing (scRNA-seq) is leading the advances in this topic and comprises a vast array of different methodologies. scRNA-seq and its variants are more and more used in life science and biomedical research since they provide unbiased transcriptomic sequencing of large populations of individual cells. These methods go beyond the previous “bulk” methodologies and sculpt the biological understanding of cellular heterogeneity and dynamic transcriptomic states of cellular populations in immunology, oncology, and developmental biology fields. Despite the large burden caused by mycobacterial infections, advances in this field obtained via single-cell genomics had been comparatively modest. Nonetheless, seminal research publications using single-cell transcriptomics to study host cells infected by mycobacteria have become recently available. Here, we review these works summarizing the most impactful findings and emphasizing the different and recent single-cell methodologies used, potential issues, and problems. In addition, we aim at providing insights into current research gaps and potential future developments related to the use of single-cell genomics to study mycobacterial infection.

show abstract

Susceptibility Profiles ofMycobacterium ulceransIsolates to Streptomycin and Rifampicin in Two Districts of the Eastern Region of Ghana

Cited by 13 publications

References 28 publications

Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening

Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening

Challenges associated with the treatment of Buruli ulcer

The impact of single-cell genomics on the field of mycobacterial infection

Contact Info

Product

Resources

About